

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
05 June 2025 (05.06.2025)



(10) International Publication Number
WO 2025/111653 A1

(51) International Patent Classification:
C12N 15/113 (2010.01) A61P 25/18 (2006.01)
A61P 25/00 (2006.01)

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(21) International Application Number:
PCT/AU2024/051273

(22) International Filing Date:
28 November 2024 (28.11.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2023903841 29 November 2023 (29.11.2023) AU
2023903842 29 November 2023 (29.11.2023) AU
2023903916 04 December 2023 (04.12.2023) AU
2023903924 05 December 2023 (05.12.2023) AU
2023903927 05 December 2023 (05.12.2023) AU
2024901708 06 June 2024 (06.06.2024) AU
2024902223 17 July 2024 (17.07.2024) AU
2024903714 13 November 2024 (13.11.2024) AU

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed
contained color or greyscale and is available for download
from PATENTSCOPE

(71) Applicant: **PYC THERAPEUTICS LIMITED**
[AU/AU]; Harry Perkins Institute, 6 Verdun St, Nedlands,
Western Australia 6009 (AU).

(72) Inventors: **STIRNWEISS, Anja**; c/o PYC Therapeutics
Limited, Harry Perkins Institute, 6 Verdun St., Nedlands,
Western Australia 6009 (AU). **LANDIN, Dulce Vargas**;
c/o PYC Therapeutics Limited, Harry Perkins Institute, 6
Verdun St, Nedlands, Western Australia 6009 (AU). **NI-
CHOLS, Jessica**; c/o PYC Therapeutics Limited, Harry
Perkins Institute, 6 Verdun St, Nedlands, Western Aus-
tralia 6009 (AU). **GRAINOK, Janya**; c/o PYC Therapeu-
tics Limited, Harry Perkins Institute, 6 Verdun St, Nedlands,
Western Australia 6009 (AU). **MARTIN, Adam**; c/o PYC
Therapeutics Limited, Harry Perkins Institute, 6 Verdun St,
Nedlands, Western Australia 6009 (AU).

(74) Agent: **FB RICE PTY LTD**; Level 33, 477 Collins St, Mel-
bourne, Victoria 3000 (AU).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(54) Title: IMPROVED COMPOSITIONS AND METHODS FOR TREATMENT OF MONOGENIC NEURODEVELOPMENTAL
DISORDERS

(57) Abstract: Described herein are antisense oligonucleotides (ASOs), vectors, and related compositions and methods for increasing
endogenous expression of SHANK3 protein and uses thereof for conditions associated with SHANK3 haploinsufficiency such as Phe-
lan-McDermid syndrome.

WO 2025/111653 A1